PMID- 35992335
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220823
IS  - 2296-4185 (Print)
IS  - 2296-4185 (Electronic)
IS  - 2296-4185 (Linking)
VI  - 10
DP  - 2022
TI  - Improved repair of rabbit calvarial defects with 
      hydroxyapatite/chitosan/polycaprolactone composite scaffold-engrafted EPCs and 
      BMSCs.
PG  - 928041
LID - 10.3389/fbioe.2022.928041 [doi]
LID - 928041
AB  - Endothelial progenitor cells (EPCs) expressing vascular endothelial growth factor 
      (VEGF) and platelet-derived growth factor (PDGF) and bone marrow mesenchymal stem 
      cells (BMSCs) expressing endogenous bone morphogenetic protein-2 (BMP-2) play the 
      important role in new bone formation. This study investigated the effects of a 
      porous hydroxyapatite (HA)/chitosan (CS)/polycaprolactone (PCL) composite 
      scaffold-engrafted EPCs and BMSCs on the expression of BMP-2, VEGF, and PDGF in 
      the calvarial defect rabbit model in vivo. It showed that a three-dimensional 
      composite scaffold was successfully constructed by physical interaction with a 
      pore size of 250 mum. The HA/CS/PCL scaffold degraded slowly within 10 weeks and 
      showed non-cytotoxicity. By X-ray, micro-CT examination, and H&E staining, 
      compared with the HA/CS/PCL group, HA/CS/PCL + EPCs, HA/CS/PCL + BMSCs, and 
      HA/CS/PCL + EPCs + BMSCs groups performed a more obvious repair effect, and the 
      dual factor group presented particularly significant improvement on the 
      percentages of bone volume at week 4 and week 8, with evident bone growth. 
      Osteogenesis marker (BMP-2) and vascularization marker (VEGF and PDGF) expression 
      in the dual factor group were much better than those of the HA/CS/PCL control 
      group and single factor groups. Collectively, the HA/CS/PCL composite 
      scaffold-engrafting EPCs and BMSCs is effective to repair calvarial defects by 
      regulating endogenous expression of BMP-2, VEGF, and PDGF. Thus, this study 
      provides important implications for the potential clinical application of 
      biomaterial composite scaffold-engrafted engineering cells.
CI  - Copyright (c) 2022 Yu, Xia, Leng, Chen, Zhang, Ni, Luo and Leng.
FAU - Yu, Hedong
AU  - Yu H
AD  - Department of Stomatology, Taihe Hospital, Hubei University of Medicine, Shiyan, 
      China.
AD  - Institute of Dental Research, School of Dentistry, Hubei University of Medicine, 
      Shiyan, China.
FAU - Xia, Lingyun
AU  - Xia L
AD  - Department of Stomatology, Taihe Hospital, Hubei University of Medicine, Shiyan, 
      China.
AD  - Institute of Dental Research, School of Dentistry, Hubei University of Medicine, 
      Shiyan, China.
FAU - Leng, Xieyuan
AU  - Leng X
AD  - The First Clinical College, Anhui Medical University, Hefei, China.
FAU - Chen, Yongji
AU  - Chen Y
AD  - Department of Stomatology, Taihe Hospital, Hubei University of Medicine, Shiyan, 
      China.
AD  - Institute of Dental Research, School of Dentistry, Hubei University of Medicine, 
      Shiyan, China.
FAU - Zhang, Li
AU  - Zhang L
AD  - Department of Stomatology, Taihe Hospital, Hubei University of Medicine, Shiyan, 
      China.
AD  - Institute of Dental Research, School of Dentistry, Hubei University of Medicine, 
      Shiyan, China.
FAU - Ni, Xiaobing
AU  - Ni X
AD  - Department of Stomatology, Taihe Hospital, Hubei University of Medicine, Shiyan, 
      China.
AD  - Institute of Dental Research, School of Dentistry, Hubei University of Medicine, 
      Shiyan, China.
FAU - Luo, Jie
AU  - Luo J
AD  - Department of Neurosurgery, Taihe Hospital, Hubei University of Medicine, Shiyan, 
      China.
FAU - Leng, Weidong
AU  - Leng W
AD  - Department of Stomatology, Taihe Hospital, Hubei University of Medicine, Shiyan, 
      China.
AD  - Institute of Dental Research, School of Dentistry, Hubei University of Medicine, 
      Shiyan, China.
LA  - eng
PT  - Journal Article
DEP - 20220803
PL  - Switzerland
TA  - Front Bioeng Biotechnol
JT  - Frontiers in bioengineering and biotechnology
JID - 101632513
PMC - PMC9382592
OTO - NOTNLM
OT  - BMP-2
OT  - HA/CS/PCL composite scaffold
OT  - PDGF
OT  - VEGF
OT  - bone marrow mesenchymal stem cells
OT  - calvarial defect
OT  - endothelial progenitor cells
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2022/08/23 06:00
MHDA- 2022/08/23 06:01
PMCR- 2022/01/01
CRDT- 2022/08/22 04:25
PHST- 2022/04/25 00:00 [received]
PHST- 2022/06/28 00:00 [accepted]
PHST- 2022/08/22 04:25 [entrez]
PHST- 2022/08/23 06:00 [pubmed]
PHST- 2022/08/23 06:01 [medline]
PHST- 2022/01/01 00:00 [pmc-release]
AID - 928041 [pii]
AID - 10.3389/fbioe.2022.928041 [doi]
PST - epublish
SO  - Front Bioeng Biotechnol. 2022 Aug 3;10:928041. doi: 10.3389/fbioe.2022.928041. 
      eCollection 2022.